Allarity Therapeutics, Inc. Common Stock (ALLR) Stock Price
ALLRStock
$1.41−6.00%52W
Market Cap$22.43M
P/E—
PEG Ratio—
Div yield—
Beta0.60
ALLR Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)36.49%
Price vs S&P 500 (4W)9.48%
VGM Score52.48
ALLR Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.25 | -$0.21 | +16.00%(+$0.04) | |
| Q1 2026 | -$0.22 | -$0.17 | +22.73%(+$0.05) | |
| Q4 2025 | -$0.22 | -$0.21 | +4.55%(+$0.01) | |
| Q3 2025 | -$0.23 | -$0.19 | +17.39%(+$0.04) | |
| Q2 2025 | -$0.21 | -$0.15 | +28.57%(+$0.06) |
ALLR Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ALLRAllarity Therapeutics, Inc. Common Stock | — | — | C | $1.41 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Allarity Therapeutics, Inc. Common Stock
Allarity Therapeutics is a clinical-stage pharmaceutical company developing stenoparib, an oral small-molecule inhibitor for advanced recurrent ovarian cancer. The company uses its proprietary Drug Response Predictor (DRP) technology to identify patients most likely to benefit from treatment, combining precision medicine with oncology. Operating in Denmark and the United States, Allarity is focused on addressing a significant unmet medical need in ovarian cancer treatment.